Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

May 1, 2024

https://www.globenewswire.com/news-release/2024/05/01/2873235/0/en/Palisade-Bio-s-Lead-Product-Candidate-PALI-2108-Demonstrates-Potent-Anti-Inflammatory-Effects-in-Ex-Vivo-Study-of-Whole-Blood-Samples-Challenged-with-Pro-Inflammatory-Lipopolysacch.html

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end

Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq:PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-α production in a whole blood (WB) assay. PALI-2108 is Palisade’s orally administered, locally acting, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.